share_log

Piper Sandler Downgrades AlloVir to Neutral, Lowers Price Target to $1.5

Benzinga ·  Dec 22, 2023 09:32

Piper Sandler analyst Christopher Raymond downgrades AlloVir (NASDAQ:ALVR) from Overweight to Neutral and lowers the price target from $27 to $1.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment